Ascendis Pharma Bone Diseases A/S
Clinical trials sponsored by Ascendis Pharma Bone Diseases A/S, explained in plain language.
Now part of
Ascendis Pharma A/S
ASND
NASDAQ
A subsidiary of Ascendis Pharma focused on bone disease treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Higher dose hormone therapy aims to control rare calcium disorder Results expected Jun 2027 (estimated) May already have reported ↗